Abstract

The physiological role of estrogen in the female endometrium is well established. On the basis of responses to steroid hormones (progesterone, androgen, and estrogen), the endometrium is considered to have proliferative and secretory phases. Estrogen can act in the endometrium by interacting with estrogen receptors (ERs) to induce mucosal proliferation during the proliferative phase and progesterone receptor (PR) synthesis, which prepare the endometrium for the secretory phase. Mouse knockout studies have shown that ER expression, including ERα, ERβ, and G-protein-coupled estrogen receptor (GPER) in the endometrium is critical for normal menstrual cycles and subsequent pregnancy. Incorrect expression of ERs can produce many diseases that can cause endometriosis, endometrial hyperplasia (EH), and endometrial cancer (EC), which affect numerous women of reproductive age. ERα promotes uterine cell proliferation and is strongly associated with an increased risk of EC, while ERβ has the opposite effects on ERα function. GPER is highly expressed in abnormal EH, but its expression in EC patients is paradoxical. Effective treatments for endometrium-related diseases depend on understanding the physiological function of ERs; however, much less is known about the signaling pathways through which ERs functions in the normal endometrium or in endometrial diseases. Given the important roles of ERs in the endometrium, we reviewed the published literature to elaborate the regulatory role of estrogen and its nuclear and membrane-associated receptors in maintaining the function of endometrium and to provide references for protecting female reproduction. Additionally, the role of drugs such as tamoxifen, raloxifene, fulvestrant and G-15 in the endometrium are also described. Future studies should focus on evaluating new therapeutic strategies that precisely target specific ERs and their related growth factor signaling pathways.

Highlights

  • The endometrium is the primary target tissue for estrogen

  • This review focuses on recent advances in our knowledge of the role of estrogen receptors (ERs) in the endometrium, animal models of ER deficiency in the uterus, and how ERs are involved in endometrial diseases and pharmacological treatments

  • This study indicated that the antiproliferative effect of androgen treatment in the endometrium is associated with increased ERb expression and that ERa may promote endometrial proliferation

Read more

Summary

Introduction

The endometrium is the primary target tissue for estrogen. The main function of the endometrium is to prepare for implantation and to maintain the pregnancy after embryo implantation. NA steroid hormone levels are similar to wild-type females heterozygous for the EAAE ERa mutations are fertile infertile infertile high serum E2 levels increased DNA synthesis, and transcription of the PR, lactoferrin, and glucose-6-phosphate dehydrogenase genes enlargement of the lumen; increase in volume and protein content of uterine secretion; induction of the luminal epithelial secretory protein reproductive tract normal have grossly enlarged uteri with cystic hyperplasia inhibited PR and AR mRNA and protein expression hyperproliferation and loss of differentiation in the uterine epithelium the inability of E2 to induce uterine epithelial proliferation; has an ERa null–like phenotype; with impaired uterine growth and transcriptional activity; the hypoplastic uteri the uterine epithelial E2-specific loss of response; increased uterine apoptosis have hypoplastic uterine tissue and rudimentary mammary glands similar to ERaKO mice ERaAF-1 is required for E2-induced uterine epithelial cell proliferation

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call